Drugs / Genetically modified DCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01956630 | Sep 2013 → Sep 2016 | acute leukemia | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Genetically modified DCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01956630 ↗ |
| Known as | gmDC | “We generated a genetically modified DC (gmDC) vaccine to perform immunotherapy.” PMID 29415891 ↗ Feb 2018 |
| Action | Inhibit | “an RNA interference moiety to suppress SOCS1” PMID 29415891 ↗ Feb 2018 |
| Modality | Vaccine | “We generated a genetically modified DC (gmDC) vaccine to perform immunotherapy.” PMID 29415891 ↗ Feb 2018 |
| Route | Subcutaneous | “Patients received four subcutaneous injections of 2-5×10e7 cells of DCs at the groin, axilla, and neck respectively on days 7, 9, 11, and 13” NCT01956630 ↗ |
| Target | SOCS1 | “an RNA interference moiety to suppress SOCS1” PMID 29415891 ↗ Feb 2018 |